Evofem Biosciences Announces First Patient Enrolled in Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea
- Tuesday, October 20, 2020, 7:03
- Finance
- Add a comment
SAN DIEGO, Oct. 20, 2020 /PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced enrollment of the first patient in its pivotal Phase 3 clinical trial evaluating the safety and efficacy of EVO100 for the prevention of urogenital chlamydia and gonorrhea in women. “We are…
About the Author
adminasapcorp has written 41562 stories on this site.